Subantimicrobial-dose doxycycline treatment increases serum cholesterol efflux capacity from macrophages.
Subantimicrobial-dose doxycycline treatment increases serum cholesterol efflux capacity from macrophages.
复制标题
DOI：
10.1007/s00011-013-0626-z
复制
发表时间：
2013-07
影响因子：
6.7
通讯作者：
Sorsa, Timo
中科院分区：
文献类型：
--
作者：
Salminen, Aino;Pussinen, Pirkko J.;Payne, Jeffrey B.;Stoner, Julie A.;Jauhiainen, Matti;Golub, Lorne M.;Lee, Hsi-Ming;Thompson, David M.;Sorsa, Timo
据报道，亚微生物剂量多西环素(SDD)治疗可以减轻慢性炎症的严重程度，并提高血清高密度脂蛋白(HDL)水平。我们在一项双盲、安慰剂对照的临床试验中确定了SDD是否影响血清促进巨噬细胞清除胆固醇的能力。将45例患有牙周炎的绝经后骨质疏松症妇女随机分为安慰剂(n=26)和多西环素片(20 mg，n=19)，每日2次，疗程2年。分别在基线、1年和2年预约时采集血清样本。测定培养的人巨噬细胞(THP-1)血清胆固醇流出能力。与基线(P<；每个时间点0.04)相比，SDD受试者在两个时间点均表现出血清介导的巨噬细胞胆固醇外流显著增加。在第一年的随访中，SDD受试者的平均胆固醇流出水平(单位变化)比安慰剂受试者高出3.0%(p=0.010)，而两年的变化没有显著差异。两组间载脂蛋白A-I、载脂蛋白A-II、血清淀粉样蛋白A水平变化无显著差异。我们的结果表明，SDD治疗可能通过增加血清胆固醇流出能力来降低该患者患心血管疾病的风险。
Subantimicrobial dose doxycycline (SDD) treatment has been reported to reduce the severity of chronic inflammation and to increase serum HDL cholesterol. We determined in a double-blind, placebo-controlled clinical trial, whether SDD affects the ability of serum to facilitate cholesterol removal from macrophages. Forty-five postmenopausal osteopenic women with periodontitis were randomly assigned to take placebo (n=26) or doxycycline hyclate (20 mg, n=19) tablets twice daily for 2 years. Serum samples were collected at baseline, 1-year, and 2-year appointments. The cholesterol efflux capacity of serum from cultured human macrophages (THP-1) was measured. SDD subjects demonstrated a significant increase in serum-mediated cholesterol efflux from macrophages at both time points, compared to baseline (p < 0.04 for each). Mean cholesterol efflux levels over the first year of follow-up were 3.0 percentage points (unit change) higher among SDD subjects compared to placebo subjects (p = 0.010), while there was no significant difference in 2-year changes. There were no significant differences in the changes of apolipoprotein A-I, apolipoprotein A-II, or serum amyloid A levels between the groups. Our results suggest that SDD treatment may reduce the risk of cardiovascular disease in this patient group by increasing the cholesterol efflux capacity of serum.
登录
查看更多内容
DOI：
10.1161/01.atv.0000121571.78696.dc
发表时间：
2004-04-01
影响因子：
8.7
作者：
Brown, DL;Desai, KK;Golub, LM
通讯作者：
Golub, LM
影响因子：
6.7
作者：
Payne, Jeffrey B.;Stoner, Julie A.;Golub, Lorne M.
通讯作者：
Golub, Lorne M.
DOI：
10.1161/atvbaha.109.199158
发表时间：
2010-04
期刊：
Arteriosclerosis, thrombosis, and vascular biology
影响因子：
--
作者：
de la Llera-Moya M;Drazul-Schrader D;Asztalos BF;Cuchel M;Rader DJ;Rothblat GH
通讯作者：
Rothblat GH
影响因子：
--
作者：
O'Dell, JR;Elliott, JR;Leff, RD
通讯作者：
Leff, RD
影响因子：
9.8
作者：
SAMMALKORPI, K;VALTONEN, V;TASKINEN, MR
通讯作者：
TASKINEN, MR